Methods and kits are disclosed for use in the analysis of microsatellite instability in genomic dna. Methods and kits are also disclosed which can be used to detect microsatellite instability dna present in biological materials, such as tumors. The methods and kits of the present invention can be used to detect or diagnose diseases associated with microsatellite instability, such as certain types of cancer.
|
1. A kit for detecting microsatellite instability in a human dna sample from tumor cells, from cells suspected of being cancerous, or from other biological material suspected of being cancerous, the kit comprising oligonucleotide primers for co-amplifying a set of at least three quasi monomorphic loci of the dna sample.
19. A kit for amplifying a set of at least one quasi monomorphic locus for detecting microsatellite instability in a human dna sample from tumor cells, from cells suspected of being cancerous, or from other biological material suspected of being cancerous, the kit comprising primers for amplifying a set of at least one quasi monomorphic locus selected from the group consisting of MONO-11 and MONO-15.
28. A kit for detecting microsatellite instability in a human dna sample from tumor cells, from cells suspected of being cancerous, or from other biological material suspected of being cancerous, the kit comprising primers for co-amplifying a set of loci comprising at least one tetranucleotide repeat locus selected from the group consisting of D1S547, D1S1677, D2S1790, D3S2432, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D9S2169, D10S1426, D10S2470, and D17S1294.
3. The kit of
4. The kit of
9. The kit of
11. The kit of
SEQ ID NO:1 and SEQ ID NO:60 when the locus is BAT-25,
SEQ ID NO:61 and SEQ ID NO:62 when the locus is BAT-26,
SEQ ID NO:7 and SEQ ID NO:8 when the locus is MONO-15, and
SEQ ID NO:5 and SEQ ID NO:6 when the locus is MONO-11.
12. The kit of
14. The kit of
15. The kit of
16. The kit of
17. The kit of
18. The kit of
29. The kit of
30. The kit of
31. The kit of
32. The kit of
33. The kit of
at least two mononucleotide repeat loci selected from the group consisting of BAT-25, BAT-26, MONO-11, and MONO-15; and
at least three tetranucleotide repeat loci selected from the group consisting of FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S818, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.
34. The kit of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a divisional of U.S. patent application Ser. No. 11/037,321, filed Jan. 18, 2005, which is a continuation of U.S. patent application Ser. No. 09/663,020, filed Sep. 15, 2000, now U.S. Pat. No. 6,844,152, issued Jan. 18, 2005, which applications are incorporated by reference herein in their entireties.
This invention was made using U.S. government Small Business Innovation Research Program Grant CA76834-02 from the National Institutes of Health. The U.S. government retains certain rights to the invention.
This invention relates to the detection of instability in regions of genomic DNA containing simple tandem repeats, such as microsatellite loci. The invention particularly relates to multiplex analysis for the presence or absence of instability in a set of microsatellite loci in genomic DNA from cells, tissue, or bodily fluids originating from a tumor. The invention also relates to the use of microsatellite instability analysis in the detection and diagnosis of cancer and predisposition for cancer.
Microsatellite loci of genomic DNA have been analyzed for a wide variety of applications, including, but not limited to, paternity testing, forensics work, and in the detection and diagnosis of cancer. Cancer can be detected or diagnosed based upon the presence of instability at particular microsatellite loci that are unstable in one or more types of tumor cells.
A microsatellite locus is a region of genomic DNA with simple tandem repeats that are repetitive units of one to five base pairs in length. Hundreds of thousands of such microsatellite loci are dispersed throughout the human genome. Microsatellite loci are classified based on the length of the smallest repetitive unit. For example, loci with repetitive units of 1 to 5 base pairs in length are termed “mono-nucleotide”, “di-nucleotide”, “tri-nucleotide”, “tetra-nucleotide”, and “penta-nucleotide” repeat loci, respectively.
Each microsatellite locus of normal genomic DNA for most diploid species, such as genomic DNA from mammalian species, consists of two alleles at each locus. The two alleles can be the same or different from one another in length and can vary from one individual to the next. Microsatellite alleles are normally maintained at constant length in a given individual and its descendants; but, instability in the length of microsatellites has been observed in some tumor types (Aaltonen et al., 1993, Science 260:812-815; Thibodeau et al., 1993 Science 260:816-819; Peltomaki et al., 1993 Cancer Research 53:5853-5855; Ionov et al., 1993 Nature 363:558-561). This form of genomic instability in tumors, termed microsatellite instability (hereinafter, “MSI”), is a molecular hallmark of the inherited cancer syndrome Hereditary Nonpolyposis Colorectal Cancer (hereinafter, “HNPCC”). The cause of MSI in HNPCC is thought to be a dysfunctional DNA mismatch repair system that fails to reverse errors that occur during DNA replication (Fishel et al., 1993 Cell 75:1027-38; Leach et al., 1993 Cell 75:215-25; Bronner et al., 1994 Nature 368:258-61; Nicolaides et al., 1994 Nature 371:75-80; Miyaki et al., 1997 Nat Genetics 17:271-2). Insertion or deletion of one or more repetitive units during DNA replication persists without mismatch repair and can be detected as length polymorphisms by comparison of allele sizes found in microsatellite loci amplified from normal and tumor DNA samples (Thibodeau et al, 1993, supra).
MSI has been found in over 90% of HNPCC and in 10-20% of sporadic colorectal tumors (Liu et al., 1996 Nature Med 2:169-174; Thibodeau et al., 1993, supra; Ionov et al., 1993 Nature 363:558-561; Aaltonen et al., 1993 Science 260: 812-816; Lothe et al., 1993 Cancer Res. 53: 5849-5852). However, MSI is not limited to colorectal tumors. MSI has also been detected in pancreatic cancer (Han et al., 1993 Cancer Res 53:5087-5089) gastric cancer (Id.; Peltomaki et al., 1993 Cancer Res 53:5853-5855; Mironov et al., 1994 Cancer Res 54:41-44; Rhyu et al., 1994 Oncogene 9:29-32; Chong et al., 1994 Cancer Res 54:4595-4597), prostate cancer (Gao et al., 1994 Oncogene 9:2999-3003), endometrial cancer (Risinger et al., 1993 Cancer Res 53:5100-5103; Peltomaki et al., 1993 Cancer Res 53:5853-5855), and breast cancer (Patel et al., 1994 Oncogene 9:3695-3700).
The genetic basis of HNPCC is thought to be a germ-line mutation in one of several DNA mismatch repair genes (hereinafter “MMR”) (Leach et al., 1993 Cell 75:1215-1225; Fishel et al., 1993 Cell 75:1027-38; Leach et al., 1993 Cell 75:215-25; Bronner et al., 1994 Nature 368:258-61; Nicolaides et al., 1994 Nature 371:75-80; Miyaki et al., 1997 Nat Genetics 17:271-2; Papadopoulos et al., 1994 Science 263:1625-1629). Among HNPCC patients, 50-60% have been reported to carry inherited mutations in two mismatch repair genes, MSH2 and MLH1 (Kolodner et al., 1999 Cancer Research 59:5068:5074). Moreover, 70-100% of HNPCC cases whose tumors manifest a high frequency MSI (hereinafter “MSI-H”) phenotype reportedly have germ-line mutations in these two genes. Few germ-line mutations in MSH6, MSH3, PMS1 and PMS2 genes have been reported in HNPCC patients, indicating that inherited mutations in these mismatch repair genes play a minor role in HNPCC (Peltomaki et al., 1997 Gastroenterology 113:1146-1158; Liu et al., 1996 Nat Med 2:169-174; Kolodner et al., 1999 Cancer Research 59:5068-5074). Without functional repair proteins, errors that occur during replication are not repaired leading to high mutation rates and increased likelihood of tumor development.
Repetitive DNA is particularly sensitive to errors in replication and therefore dysfunctional mismatch repair systems result in widespread alterations in microsatellite regions. A study of yeast cells without functional mismatch repair systems showed a 2800, 284, 52, and 19 fold increase in mutation rates in mono-, di-, tri-, tetra-, and penta-nucleotide repeats, respectively (Sia et al., 1997 Molecular and Cellular Biology 17:2851-2858). Mutations in mismatch repair genes are not thought to play a direct role in tumorigenesis, but rather act by allowing DNA replication errors to persist. Mismatch repair deficient cells have high mutation rates and if these mutations occur in genes involved in tumorigenesis the result can lead to the development of cancer. MSI positive tumors have been found to carry somatic frameshift mutations in mono-nucleotide repeats in the coding region of several genes involved in growth control, apoptosis, and DNA repair (e.g., TGFBRII, BAX, IGFIIR, TCF4, MSH3, MSH6) (Planck et al., 2000 Genes, Chromosomes & Cancer 29:33-39; Yamamoto et al., 1998 Cancer Research 58:997-1003; Grady et al., 1999 Cancer Research 59:320-324; Markowitz et al., 1995 Science 268:1336-1338; Parsons et al., 1995 Cancer Research 55:5548-5550). The most commonly altered locus is TGFBRII, in which over 90% of MSI-H colon tumors have been found to contain a mutation in the 10 base polyadenine repeat present in the gene (Markowitz et al., 1995 Science 268:1336-1338).
MSI occurs in almost all HNPCC tumors regardless of which mismatch repair gene is involved. MSI has also been shown to occur early in tumorigenesis. These two factors contribute to making MSI analysis an excellent diagnostic test for the detection of HNPCC. In addition, MSI analysis can serve as a useful pre-screening test to identify potential HNPCC patients for further genetic testing. MSI analysis of sporadic colorectal carcinomas is also desirable, since the occurrence of MSI correlates with a better prognosis (Bertario et al., 1999 International J Cancer 80:83-7).
One long-standing problem with diagnosing HNPCC is that colon tumor biopsies from a person with HNPCC look the same pathologically as a sporadic colon tumor, making diagnosis of the syndrome difficult. Since prognosis, therapy and follow-up will be different for patients with HNPCC, it is important to find more definitive diagnostic methods. However, mutation detection in HNPCC patients remains difficult because there are at least 5 known MMR genes which are large genes without known hot spots for mutations. Direct gene sequencing remains the most precise method of mutation detection, but is time consuming and expensive (Terdiman et al., 1999 The American Journal of Gastroenterology 94:23544-23560). In addition, high sensitivity and specificity can be difficult to obtain with sequencing alone because many mutations that are detected may be harmless polymorphisms that have no affect on the function of the mismatch repair proteins.
DNA analysis of microsatellite loci makes it theoretically possible to develop a blood test for use in the detection of specific types of cancer. Early studies have shown that tumor DNA is released into the circulation, and is present in particularly high concentrations in plasma and serum in a number of different types of cancer (Leon et al., 1977 Cancer Res 37:646-650; Stroun et al., 1989 Oncology 46:318-322). Since then, DNA released into the blood from several different types of tumors has been detected by analysis of microsatellite DNA using the polymerase chain reaction (hereinafter, “PCR”) (Hibi et al., 1998 Cancer Research 58:1405-1407; Chen et al., 1999 Clinical Cancer Research 5:2297-2303; Kopreski et al., 1999 Clinical Cancer Research 5:1961-1965; Fujiwara et al., 1999 Cancer Research 59:1567-1571; Chen et al., 1996 Nature Medicine 2:1033-1034; Goessl et al., 1998 Cancer Research 58:4728-4732; Miozzo et al., 1996 Cancer Research 56:2285-2288).
The first tumor-specific gene sequences detected in blood from patients with cancer were mutated K-ras genes (Vasioukhin et al., 1994 Br. J Haematol 86: 774-779; Sorenson et al., 1994 Cancer Epidemiol. Biomark. Prev. 3:67-71; Sorenson et al., 2000 Clinical Cancer Research 6:2129-2137; Anker et al., 1997 Gastroenterology 112:1114-1120). More recently, detection of microsatellite instability in soluble tumor DNA from plasma and serum originating from head and neck squamous cell cancers (Nawroz et al., 1996 Nature Med 2:1035-1037) and small cell lung cancers (Chen et al., 1996 Nature Med 2:1033-1035) has been shown. These successes have stimulated searches for microsatellite instability in circulating tumor DNA from many other cancer types. Hibi et al., used microsatellite markers to search for the presence of genetic alterations in serum DNA from colon cancer patients (Hibi, K. et al., 1998 Cancer Research 58:1405-1407). Hibi et al., also reported that eighty percent of primary tumors in the colon cancer patients displayed MSI and/or loss of heterozygosity (hereinafter, “LOH”), another type of mutation discussed below. No microsatellite or LOH mutations were detected in paired serum DNA. However, identical K-ras mutations were found in corresponding tumor and serum DNAs, indicating that tumor DNA was present in the blood. (Id.)
The detection of circulating tumor cells and micrometastases may also have important prognostic and therapeutic implications. Because disseminated tumor cells are present in very small numbers, they are not easily detected by conventional immunocytological tests, which can only detect a single tumor cell among 10,000 to 100,000 normal cells (Ghoussein et al., 1999 Clinical Cancer Research 5:1950-1960). More sensitive molecular techniques based on PCR amplification of tumor-specific abnormalities in DNA or RNA have greatly facilitated detection of occult (hidden) tumor cells. PCR-based tests capable of routinely detecting one tumor cell in one million normal cells have been devised for identification of circulating tumor cells and micrometastases in leukemias, lymphomas, melanoma, neuroblastoma, and various types of carcinomas. (Id.)
Most targets for detection of disseminated tumor cells have been mRNAs. However, some DNA targets have been used successfully, including K-ras mutations in colon cancers, as noted above. The presence of microsatellite instability in some types of tumor cells raises the possibility that these tumor specific mutations created by the instability could serve as a target for PCR-based detection of occult tumor cells.
There has been considerable controversy about how to precisely define and accurately measure MSI (Boland, 1998 Cancer Research 58:5248-5257). Reports on the frequency of MSI in various tumors ranges considerably. For example, different studies have reported ranges of 3% to 95% MSI for the frequency of MSI in bladder cancer (Gonzalez-Zulueta et al, 1993 Cancer Research 53:28-30; Mao et al., 1996 PNAS 91:9871-9875). One problem with defining MSI is that it is both tumor specific and locus dependent (Boland et al. 1998, supra). Thus, the frequency of MSI observed with a particular tumor type in a single study will depend on the number of tumors analyzed, the number of loci investigated, how many loci need to be altered to score a tumor as having MSI and which particular loci were included in the analysis. To help resolve these problems, the National Cancer Institute sponsored a workshop on MSI to review and unify the field (Id.). As a result of the workshop a panel of five microsatellites was recommended as a reference panel for future research in the field. This panel included two mono-nucleotide loci BAT-25, BAT-26, and three dinucleotide loci D5S346, D2S123, D17S250.
One particular problem in MSI analysis of tumor samples occurs when one of the normal alleles for a given marker is missing due to LOH, and no other novel fragments are present for that marker (Id.). One cannot easily discern whether this represents true LOH or MSI in which the shifted allele has co-migrated with the remaining wild-type allele. In cases like this, the recommendation from the NCI workshop on MSI was not to call it as MSI. One way to minimize this type of problem would be to use loci that displayed low frequency of LOH in colon tumors.
Clinical diagnostic assays used for determining treatment and prognosis of disease require that the tests be highly accurate (low false negatives) and specific (low false positive rate). Many informative microsatellite loci have been identified and recommended for MSI testing (Boland et al. 1998, supra). However, even the most informative microsatellite loci are not 100% sensitive and 100% specific. To compensate for the lack of sensitivity using individual markers, multiple markers can be used to increase the power of detection. The increased effort required to analyze multiple markers can be offset by multiplexing. Multiplexing allows simultaneous amplification and analysis of a set of loci in a single tube and can often reduce the total amount of DNA required for complete analysis. To increase the specificity of an MSI assay for any given type of cancer, it has been recommended that the panel of five highly informative microsatellite loci identified at the National Institute Workshop (see above) be modified to substitute or add other loci of equal utility (Boland et al. 1998, supra, at p. 5250). Increased information yielded from amplifying and analyzing greater numbers of loci results in increased confidence and accuracy in interpreting test results.
Multiplex MSI analysis solves problems of accuracy and discrimination of MSI phenotypes, but the additional complexity can make analysis more challenging. For example, when microsatellite loci are co-amplified and analyzed in a multiplex format, factors affecting ease and accuracy of data interpretation become much more essential. One of the primary factors affecting accurate data interpretation is the amount of stutter that occurs at microsatellite loci during PCR (Bacher & Schumm, 1998 Profiles in DNA 2:3-6; Perucho, 1999 Cancer Research 59:249-256). Stutter products are minor fragments produced by the PCR process that differ in size from the major allele by multiples of the core repeat unit. The amount of stutter observed in microsatellite loci tends to be inversely correlated with the length of the core repeat unit. Thus, stutter is most severely displayed with mono- and di-nucleotide repeat loci, and to a lesser degree with tri-, tetra-, and penta-nucleotide repeats (Bacher & Schumm, 1998, supra). Use of low stutter loci in multiplexes would greatly reduce this problem. However, careful selection of loci is still necessary in choosing low stutter loci because percent stutter can vary considerably even within a particular repeat type (Micka et al., 1999 Journal of Forensic Sciences 44: 1-15).
Microsatellite multiplex systems have been primarily developed for use in genotyping, mapping studies and DNA typing applications. These multiplex systems are designed to allow co-amplification of multiple microsatellite loci in a single reaction, followed by detection of the size of the resulting amplified alleles. For DNA typing analysis, the use of multiple microsatellite loci dramatically increases the matching probability over a single locus. Matching probability is a common statistic used in DNA typing that defines the number of individuals you would have to survey before you would find the same DNA pattern as a randomly selected individual. For example, a four locus multiplex system (GenePrint™ CTTv Multiplex System, Promega) has a matching probability of 1 in 252.4 in African-American populations, compared to an eight locus multiplex system (GenePrint™ PowerPlex™ 1.2 System, Promega) which has a matching probability of 1 in 2.74×108 (Proceedings: American Academy of Forensic Sciences (Feb. 9-14, 1998), Schumm, James W. et al., p. 53, B88; Id. Gibson, Sandra D. et al., p. 53, B89; Id., Lazaruk, Katherine et al., p. 51, B83; Sparkes, R. et al., 1996 Int J Legal Med 109:186-194). Other commercially available multiplex systems for DNA typing include AmpF/STR Profiler™ and AmpF/STR COfiler™(AmpFISTR Profiler™ PCR Amplification Kit User's Manual (1997), i-viii and 1-1 to 1-10; and AmpFISTR COfiler™ PCR Amplification Kit User Bulletin (1998), i-iii and 1-1 to 1-10, both published by Perkin-Elmer Corp). In addition to multiplexes for DNA typing, a few multiplex microsatellite systems have been developed for the detection of diseases, such as cancer. One such system has been developed by Roche Diagnostics, the “HNPCC Microsatellite Instability Test”, in which five MSI loci (BAT25, BAT26, D5S436, D17S250, and D2S123) are co-amplified and analyzed. Additional systems are needed, particularly systems that include additional loci displaying high sensitivity to MSI and low stutter for easy and accuracy of analysis.
The materials and methods of the present invention are designed for use in multiplex analysis of particular microsatellite loci of human genomic DNA from various sources, including various types of tissue, cells, and bodily fluids. The present invention represents a significant improvement over existing technology, bringing increased power of discrimination, precision, and throughput to the analysis of MSI loci and to the diagnosis of illness, such as cancer, related to mutations at such loci.
The present invention provides methods and kits for amplifying and analyzing microsatellite loci or sets of microsatellite loci. The present invention also provides methods and kits for detecting cancer in an individual by co-amplifying multiple microsatellite loci of human genomic DNA originating from tumor tissue or cancerous cells.
In one aspect, the present invention provides a method of analyzing micro-satellite loci, comprising: (a) providing primers for co-amplifying in a single tube a set of at least three microsatellite loci of genomic DNA, comprising at least one mono-nucleotide repeat locus and at least two tetra-nucleotide repeat loci; (b) co-amplifying the set of at least three microsatellite loci from a sample of genomic DNA in a multiplex amplification reaction, using the primers, thereby producing amplified DNA fragments; and (c) determining the size of the amplified DNA fragments.
In another aspect, the present invention provides a method of co-amplifying the set of at least three microsatellite loci of at least two different samples of genomic DNA, a first sample originating from normal non-cancerous biological material from an individual and a second sample originating from a second biological material from the individual. The at least two samples of human genomic DNA are co-amplified in separate multiplex amplification reactions, using primers to each of the loci in the set of at least three microsatellite loci. The size of the resulting amplified DNA fragments from the two multiplex reactions are compared to one another to detect instability in any of the at least three microsatellite loci of the second sample of human genomic DNA.
Another embodiment of the present invention is a method of analyzing at least one mono-nucleotide repeat locus of human genomic DNA selected from the group consisting of MONO-11 and MONO-15. The method of analyzing the at least one mono-nucleotide repeat locus selected from the group consisting of MONO-11 and MONO-15 comprises the steps of: (a) providing at least one primer of the at least one mono-nucleotide repeat locus; (b) amplifying the at least one mono-nucleotide repeat locus from a sample of genomic DNA originating from a biological material from an individual human subject, using the at least one primer, thereby producing an amplified DNA fragment; and (c) determining the size of the amplified DNA fragments. The amplified DNA fragments are preferably analyzed to detect microsatellite instability at the at least one mono-nucleotide repeat locus by comparing the size of the amplified DNA fragments to the most commonly observed allele size at that locus in a human population. Alternatively, the method is used to amplify the at least one mono-nucleotide repeat locus of a sample of human genomic DNA from normal non-cancerous biological material from an individual, and microsatellite instability is detected by comparing the resulting amplified DNA fragments to those obtained in step (b).
Another embodiment of the present invention is a kit for the detection of microsatellite instability in DNA isolated from an individual subject, comprising a single container with oligonucleotide primers for co-amplifying a set of at least three microsatellite loci comprising one mono-nucleotide locus and two tetra-nucleotide loci.
The various embodiments of the method and kit of the present invention, described briefly above, are particularly suited for use in the detection of MSI in tumor cells or cancerous cells. Specifically, the method or kit of the present invention can be used to amplify at least one mono-nucleotide repeat locus selected from the group consisting of MONO-11 and MONO-15 or the set of at least three microsatellite loci comprising at least one mono-nucleotide repeat locus and at least two tetranucleotide repeat loci of at least one sample of genomic DNA from biological material, such as tissue or bodily fluids, preferably biological material containing or suspected of containing DNA from tumors or cancerous cells. For monomorphic or quasi-monomorphic loci, such as MONO-11 and MONO-15, one can compare the resulting pattern to the pattern produced by amplifying normal DNA from any individual in a population with a standard pattern at that locus. However, it is preferable to use DNA from normal tissue of the same individual from whom the tumor DNA was obtained, in order to ensure that a positive result does not reflect a germline mutation, rather than MSI.
The method and kit can also be used to compare the results of multiplex amplification of DNA from normal tissue of an individual to the results of multiplex amplification of DNA from other biological material from the same individual. Use of this particular embodiment of the method of the present invention to detect MSI in tumor cells by comparison to normal cells is illustrated in
Advantages and a fuller appreciation of the specific attributes of this invention will be gained upon an examination of the following figures, detailed description of preferred embodiments, and appended claims. It is expressly understood that the drawings are for the purposes of illustration and description only, and are not intended as a definition of the limits of the invention.
A. Definitions
The following definitions are intended to assist in providing a clear and consistent understanding of the scope and detail of the following terms, as used to describe and define the present invention:
“Allele”, as used herein, refers to one of several alternative forms of a gene or DNA sequence at a specific chromosomal location (locus). At each autosomal locus an individual possesses two alleles, one inherited from the father and one from the mother.
“Amplify”, as used herein, refers to a process whereby multiple copies are made of one particular locus of a nucleic acid, such as genomic DNA. Amplification can be accomplished using any one of a number of known means, including but not limited to the polymerase chain reaction (PCR) (Saiki, R. K., et al., 1985 Science 230: 1350-1354), transcription based amplification (Kwoh, D. Y., and Kwoh, T. J., American Biotechnology Laboratory, October, 1990) and strand displacement amplification (SDA) (Walker, G. T., et al., 1992 Proc. Natl. Acad. Sci., U.S.A. 89: 392-396).
“Co-amplify”, as used herein, refers to a process whereby multiple copies are made of two or more loci in the same container, in a single amplification reaction.
“DNA polymorphism”, as used herein, refers to the existence of two or more alleles for a given locus in the population. “Locus” or “genetic locus”, as used herein, refers to a unique chromosomal location defining the position of an individual gene or DNA sequence. “Locus-specific primer”, as used herein, refers to a primer that specifically hybridizes with a portion of the stated locus or its complementary strand, at least for one allele of the locus, and does not hybridize efficiently with other DNA sequences under the conditions used in the amplification method.
“Loss of Heterozygosity” (hereinafter, “LOH”), as used herein, refers to the loss of alleles on one chromosome detected by assaying for markers for which an individual is constitutionally heterozygous. Specifically, LOH can be observed upon amplification of two different samples of genomic DNA from a particular subject, one sample originating from normal biological material and the other originating from a tumor or pre-cancerous tissues. The tumor exhibits LOH if DNA from the normal biological material produces amplified alleles of two different lengths and the tumor samples produces only one of the two lengths of amplified alleles at the same locus.
“Microsatellite Locus”, as used herein, refers to a region of genomic DNA that contains short, repetitive sequence elements of one (1) to seven (7), more preferably one (1) to five (5), most preferably one (1) to four (5) base pairs in length. Each sequence repeated at least once within a microsatellite locus is referred to herein as a “repeat unit.” Each microsatellite locus preferably includes at least seven repeat units, more preferably at least ten repeat units, and most preferably at least twenty repeat units.
“Microsatellite Instability” (hereinafter, “MSI”), as used herein, refers to a form of genetic instability in which alleles of genomic DNA obtained from certain tissue, cells, or bodily fluids of a given subject change in length at a microsatellite locus. Specifically, MSI can be observed upon amplification of two different samples of genomic DNA from a particular subject, such as DNA from healthy and cancerous tissue, wherein the normal sample produces amplified alleles of one or two different lengths and the tumor sample produces amplified alleles wherein at least one of the alleles is of a different length from the amplified alleles of the normal sample of DNA at that locus. MSI generally appears as a result of the insertion or deletion of at least one repeat unit at a microsatellite locus.
“MSI-H”, as used herein, is a term used to classify tumors as having a high frequency of MSI. When five microsatellite loci are analyzed, such as the five microsatellite loci of selected by a workshop on HNPCC at the National Cancer Institute in 1998 for use in the detection of HNPCC, a tumor is classified as MSI-H when at least two of the loci show instability (Boland, 1998 Cancer Research 58: 5248-5257). When more than five microsatellite loci are analyzed, a tumor is classified as MSI-H when at least 30% of the microsatellite loci of genomic DNA originating from the tumor is are found to be unstable.
“MSI-L”, as used herein, is a term used to classify tumors as having a low frequency of MSI. When five microsatellite loci are analyzed, such as the five microsatellite loci of selected by a workshop on HNPCC at the National Cancer Institute in 1998 for use in the detection of HNPCC, a tumor is classified as MSI-L when only one of the loci shows instability. When more than five microsatellite loci are analyzed, a tumor is classified as MSI-L when less than 30% of the microsatellite loci of genomic DNA originating from the tumor is are found to be unstable. MSI-L tumors are thought to represent a distinct mutator phenotype with potentially different molecular etiology than MSI-H tumors (Thibodeau, 1998; Wu et al., 1999, Am J Hum Genetics 65:1291-1298). To accurately distinguish MSI-H and MSI-L phenotypes it has been recommended that more than five microsatellite markers be analyzed (Boland, 1998, supra; Frazer et al., 1999 Oncology Research 6:497-505).
“MSS”, as used herein, refers to tumors which are microsatellite stable, when no microsatellite loci exhibit instability. The distinction between MSI-L and MSS can also only be accomplished when a significantly greater number of markers than five are utilized. The National Cancer Institute recommended use of an additional 19 mono- and di-nucleotide repeat loci for this purpose, and for the purpose of making clearer distinctions between MSI-H and MSI-L tumors, as described above (Boland, 1998, supra).
“MSI-L/S”, as used herein, refers to all classified as either MSI-L or MSS.
“Microsatellite marker”, as used herein, refers to a fragment of genomic DNA which includes a microsatellite repeat and nucleic acid sequences flanking the repeat region.
“Monomorphic”, as used herein, refers to a locus of genomic DNA where only one allele pattern has been found to be present in the normal genomic DNA of all members of a population.
“Nucleotide”, as used herein, refers to a basic unit of a DNA molecule, which includes one unit of a phosphatidyl back bone and one of four bases, adenine (“A”); thymine (“T”); guanine (“G”); and cytosine (“C”).
“Polymerase chain reaction” or “PCR”, as used herein, refers to a technique in which cycles of denaturation, annealing with primer, and extension with DNA polymerase are used to amplify the number of copies of a target DNA sequence by approximately 106 times or more. The polymerase chain reaction process for amplifying nucleic acid is covered by U.S. Pat. Nos. 4,683,195 and 4,683,202, which are incorporated herein by reference for a description of the process.
“Primer”, as used herein, refers to a single-stranded oligonucleotide or DNA fragment which hybridizes with a strand of a locus of target DNA in such a manner that the 3′ terminus of the primer may act as a site of polymerization using a DNA polymerase enzyme.
“Primer pair”, as used herein, refers to a pair of primers which hybridize to opposite strands a target DNA molecule, to regions of the target DNA which flank a nucleotide sequence to be amplified.
“Primer site”, as used herein, refers to the area of the target DNA to which a primer hybridizes.
“Quasi-monomorphic”, as used herein, refers to a locus of genomic DNA where only one allele pattern has been found to be present in the normal genomic DNA of almost all the members of a population
“Stutter”, as used herein, refers to a minor fragment observed after amplification of a microsatellite locus, one or more repeat unit lengths smaller than the predominant fragment or allele. It is believed to result from a DNA polymerase slippage event during the amplification process (Levinson & Gutman, 1987 Molecular Biology Evolution 4:203; Schlotterer and Tautz, 1992 Nucleic Acids Research 20:211).
B. Selection of Loci to be Amplified or Co-Amplified
At least one MSI locus amplified or co-amplified in each of the embodiments of the present invention illustrated and discussed herein is a mono-nucleotide repeat locus. Such loci have been shown to very susceptible to alteration in tumors with dysfunctional DNA mismatch repair systems (Parsons., 1995 supra), making such loci particularly useful for the detection of cancer and other diseases associated with dysfunctional DNA mismatch repair systems. One group of researchers reported that by amplifying and analyzing a single mono-nucleotide repeat locus, BAT-26, they were able to correctly confirm the MSI-H status of 159 out of 160 (99.4% accuracy) tumor samples (Hoang et al., 1997 Cancer Research 57:300-303).
Some mono-nucleotide repeat loci, including BAT-26, have also been identified as having quasi-monomorphic properties. Monomorphic or quasi-monomorphic properties make the comparison of normal/tumor pairs simpler, since PCR products from normal samples are generally all the same size and any alterations in tumor samples are easily identified.
The principal draw-back to using a mono-nucleotide repeat locus in the analysis of genomic DNA is that amplification of any such locus results in a large number of extraneous amplified fragments of DNA of various lengths, the product of “stutter” during the amplification reaction. Such artifacts are present to a lesser degree in the products of amplifying loci with increasingly longer repeat units. For an illustration of the relationship between repeat unit length and the presence of extraneous amplified fragments, see
When a mono-nucleotide locus is monomorphic or quasi-monomorphic, however, one can readily detect shifts in the size of an allele, indicating MSI, even in the presence of a high degree of stutter. When a locus is quasi-monomorphic, detection of shifts in size can be done by comparison of amplified alleles from genomic DNA from biological material of an individual, such as tumor tissue or bodily fluids, suspected of exhibiting microsatellite instability to the most commonly observed allele size at that locus in a population. This feature enables one to use a single standard or panel of standard allele patterns to analyze individual results, minimizing the amount of samples which must be taken from an individual in order to detect microsatellite instability in certain genomic DNA of the individual.
At least one of the microsatellite loci amplified in the method or using the kit of the present invention is preferably a mono-nucleotide repeat locus, more preferably a quasi-monomorphic mono-nucleotide repeat locus. The mono-nucleotide repeat locus selected for use in the methods and kits of the present invention is preferably unstable in cancerous biological material, but not in normal biological material. BAT-25 and BAT-26 have been identified as mono-nucleotide repeat loci useful in the identification of MSI in colorectal tumors characteristic of Hereditary Nonpolyposis Colon Cancer (Zhou et al., 1998 Genes, Chromosomes & Cancer 21:101-107; Dietmaier et al., 1997 Cancer Research 57:4749-4756; Hoang et al., 1997 Cancer Research 57:300-303). Two additional loci, identified herein as MONO-11 and MONO-15 were identified through a search of a public computerized database of sequence information (GenBank), and found to have the preferred characteristics for such loci, identified above. The search for and identification of mono-nucleotide repeat loci suitable for use in the present invention is illustrated in Example 2. Similar techniques could be used to identify other mono-nucleotide repeat loci suitable for use in the methods and kits of the present invention.
The mono-nucleotide repeat loci amplified or co-amplified according to the present methods or using the present kits are preferably quasi-monomorphic and exhibit instability in the type of tissue of interest for a given application. MONO-11 and MONO-15, have been particularly useful in the methods and kits of the present invention. Both loci are quasi-monomorphic and exhibit instability in several cancerous tumor tissues. At least one, more preferably at least two mono-nucleotide repeat microsatellite loci are amplified or co-amplified in the method of the present invention.
At least one mono-nucleotide repeat locus and at least two tetra-nucleotide repeat loci are co-amplified and analyzed according to at least some embodiments of the method and kits of the present invention. Tetra-nucleotide repeat loci inherently generate very few stutter artifacts when amplified, compared to microsatellite loci with shorter repeat units, particularly compared to mono- and di-nucleotide repeat loci. (See, e.g.,
As with any locus to be amplified in any method or using any kit of the present invention, the tetra-nucleotide repeat loci are preferably selected on the basis of being stable in the DNA of an individual except in the type of biological material of interest. Preferred tetra-nucleotide repeat loci used in the methods and kits of the present invention include: FGA, D1S518, D1S547, D1S1677, D2S1790, D3S2432, D5S818, D5S2849, D6S1053, D7S3046, D7S1808, D7S3070, D8S1179, D9S2169, D10S1426, D10S2470, D12S391, D17S1294, D17S1299, and D18S51.
Additional mono-nucleotide or tetra-nucleotide loci with the same preferred criteria described above are preferably co-amplified with the set of at least three microsatellite loci described above. However, it is contemplated that microsatellite loci other than mono-nucleotide repeat or tetra-nucleotide repeat loci could be included in the set of at least three microsatellite loci co-amplified and analyzed according to the method or using the kit of the present invention.
Preferred methods for selection of loci and sets of loci amplified and analyzed according to the methods or using the kits of the present invention are discussed further, herein below. However, once the method and materials of this invention are disclosed, additional methods of selecting loci, primer pairs, and amplification techniques for use in the method and kit of this invention are likely to be suggested to one skilled in the art. All such methods are intended to be within the scope of the appended claims.
C. Additional Screening of Loci
When the method or kit of the present invention is to be used in clinical diagnostic assays to be used to determine treatment and prognosis of disease, it must be designed to produce results which are highly accurate (low false negatives) and specific (low false positive rate). Informative microsatellite loci are preferably identified by screening, more preferably by very extensive screening (see Examples 1 and 2). However, even the most informative microsatellite loci are not 100% sensitive and 100% specific.
The power of individual markers at detecting the presence of MSI in tissue associated with a particular disease, such as cancerous tumors, can be increased tremendously by multiplexing multiple markers. Increased information yielded from amplifying and analyzing greater numbers of loci results in increased confidence and accuracy in interpreting test results. To obtain needed sensitivity in detecting or diagnosing diseases such as cancer, it has been recommended that one analyze five or more highly informative microsatellite loci (Boland, 1998 Cancer Research 58: 5248-5257). Multiplexing of microsatellite loci further simplifies MSI analysis by allowing simultaneous amplification and analysis of all multiple loci, while reducing the amount of often-limited DNA required for amplification.
Another common problem in MSI determination relates to the occurrence of an intermediate MSI phenotype where only a small percentage (<30%) of microsatellite markers are altered in tumors (Boland, 1998, supra). These MSI-low tumors are thought to represent a distinct mutator phenotype with potentially different molecular etiology than MSI-H tumors (Thibodeau et al., 1993 Science 260: 816-8; Wu et al., 1999 Am J Hum Genetics 65:1291-1298; Kolodner et al., 1999 Cancer Research 59:5068-5074; Wijnen et al., 1999 Nature Genetics 23:142-144). It is not clear however if there is a real difference between MSI-L and MSS tumors. For purposes of diagnosis, MSI-L and MSS tumors are generally considered as one stable phenotypic class. To accurately distinguish MSI-H and MSI-L phenotypes it has been recommended that multiple microsatellite markers be analyzed (Boland, 1998; Frazer, 1999 supra).
It is contemplated that when the loci are to be co-amplified and analyzed in a multiplex amplification reaction, additional factors are taken into account, including ease and accuracy of interpretation of data. One of the primary factors affecting accurate data interpretation is the amount of stutter that occurs at microsatellite loci during PCR. Tetra-nucleotide repeat loci were chosen for inclusion in the MSI multiplex analyzed according to the method and using the kit of the present invention because they display considerably less stutter that shorter repeat types like di-nucleotides (
Incidence of LOH is another factor in the selection of MSI loci to be amplified and analyzed in the methods or kits of the present invention. LOH can result in misidentification of a missing normal allele at a microsatellite marker as an indication of MSI when no other novel fragments are present for that marker. Specifically, one cannot easily discern whether this represents true LOH or MSI in which the shifted allele has co-migrated with the remaining wild-type allele. In order to minimize the problem described above, the microsatellite markers selected for use in the present methods and kits preferably exhibit a low frequency of LOH, preferably no more than about 20% LOH, more preferably no more than about 14% LOH, even more preferably, no more than about 3% LOH.
It is a relatively uncommon occurrence for a microsatellite market to possess all necessary attribute described above (i.e., high sensitivity, high specificity, low stutter, low LOH). The threshold for an MSI analysis system to be used in a diagnostic test is even higher, requiring robust and reproducible results from multiple loci in one assay using small quantities of DNA from difficult samples and be able to distinguish between MSI-L and MSI-H phenotypes. All the specific preferred mono- and tetra-nucleotide repeat loci identified herein above as being preferred for use in the present invention were found to meet each of the criteria for MSI loci suitable for use in diagnostic analysis, set forth herein above.
Additional loci selection criteria particular to the two principal types of MSI loci amplified in the preferred multiplex analysis methods and using the kits of the present loci are described below.
D. Design of Primers
Primers for one or more microsatellite loci are provided in each embodiment of the method and kit of the present invention. At least one primer is provided for each locus, more preferably at least two primers for each locus, with at least two primers being in the form of a primer pair which flanks the locus. When the primers are to be used in a multiplex amplification reaction it is preferable to select primers and amplification conditions which generate amplified alleles from multiple co-amplified loci which do not overlap in size or, if they do overlap in size, are labeled in a way which enables one to differentiate between the overlapping alleles.
Primers suitable for the amplification of individual loci preferably co-amplified according to the methods of the present invention are provided in Example 4, Table 9, herein below. Primers suitable for use in a preferred multiplex of nine loci (i.e., BAT-25, D10S1426, D3S2432, BAT-26, D7S3046, D7S3070, MONO-15, D1S518, and D7S1808) are described in Example 6, Table 11. Guidance for designing this and other multiplexes is provided, below. It is contemplated that other primers suitable for amplifying the same loci or other sets of loci falling within the scope of the present invention could be determined by one of ordinary skill in the art.
E. Design and Testing of MSI Multiplex
The method of multiplex analysis of microsatellite loci of the present invention contemplates selecting an appropriate set of loci, primers, and amplification protocols to generate amplified alleles from multiple co-amplified loci which preferably do not overlap in size or, more preferably, which are labeled in a way which enables one to differentiate between the alleles from different loci which overlap in size. Combinations of loci may be rejected for either of the above two reasons, or because, in combination, one or more of the loci do not produce adequate product yield, or fragments which do not represent authentic alleles are produced in this reaction.
The following factors are preferably taken into consideration in deciding upon which loci to include in a multiplex of the present invention. To effectively design the microsatellite multiplex, size ranges for alleles at each locus are determined. This information is used to facilitate separation of alleles between all the different loci, since any overlap could result in an allele from one locus being inappropriately identified as instability at another locus.
The amount of stutter exhibited by non-mono-nucleotide repeat loci is also preferably taken into consideration; as the amount of stutter exhibited by a locus can be a major factor in the ease and accuracy of interpretation of data. It is preferable to conduct a population study to determine the level of stutter present for each non-mono-nucleotide repeat locus. As noted above, tetra-nucleotide repeat markers display considerably less stutter that shorter repeat types like di-nucleotides and therefore can be accurately scored in MSI assays (FIGS. 2 and 3)(Bacher & Schumm, 1998 Profiles in DNA 2(2):3-6). Note that even within a class of microsatellite loci, such as tetra- and penta-nucleotide repeat loci, known to exhibit low stutter, the percent stutter can vary considerably within the repeat type (
Although at least one mono-nucleotide and at least two tetra-nucleotide repeat loci are included in the multiplex of MSI loci co-amplified according to the method or using the kit of the present invention, additional mono-nucleotide and/or tetra-nucleotide repeat loci can be included in the multiplex. It is also contemplated that multisatellite loci other than mono- or tetra-nucleotide repeat loci meeting the same or similar criteria to the criteria described above would be included in the multiplex.
The multiplex analyzed according to the present invention preferably includes a set of at least three MSI loci. It more preferably includes a set of at least five MSI loci, even more preferably a set of at least nine MSI loci. When the multiplex is a set of at least nine loci, it is most preferably a set of the following loci: BAT-25, D10 S1426, D3S2432, BAT-26, D7S3046, D7S3070, MONO-15, D1S518, and D7S1808. A list of primers suitable for use in this multiplex is provided in Table 11 of Example 6 below.
It is also contemplated that other factors, such as successful combinations of materials and methods, are taken into consideration in designing a multiplex of MSI loci. Determination of such additional factors can be determined by following the selection methods and guidelines disclosed herein, and by using techniques known to one of ordinary skill in the art of the present invention. Specifically, the same or substantially similar techniques can be used to identify the preferred MSI loci and sets of MSI loci described herein below to select primer pair sequences, and to adjust primer concentrations to identify an equilibrium in which all included loci may be amplified. In other words, once the method and materials of this invention are disclosed, various methods of selecting loci, primer pairs, and amplification techniques for use in the method and kit of this invention are likely to be suggested to one skilled in the art. All such methods are intended to be within the scope of the present claims.
F. Sources of Genomic DNA
The genomic DNA amplified or co-amplified according to the methods of the present invention originates from biological material from an individual subject, preferably a mammal, more preferably from a dog, cat, horse, sheep, mouse, rat, rabbit, monkey, or human, even more preferably from a human or a mouse, and most preferably from a human being. The biological material can be any tissue, cells, or biological fluid from the subject which contains genomic DNA. The biological material is preferably selected from the group consisting of tumor tissue, disseminated cells, feces, blood cells, blood plasma, serum, lymph nodes, urine, and other bodily fluids.
The biological material can be in the form of tissue samples fixed in formalin and embedded in paraffin (hereinafter “PET”). Tissue samples from biopsies are commonly stored in PET for long term preservation. Formalin creates cross-linkages within the tissue sample which can be difficult to break, sometimes resulting in low DNA yields. Another problem associated with formalin-fixed paraffin-embedded samples is amplification of longer fragments is often problematic. When DNA from such samples is used in multiplex amplification reactions, a significant decrease in peak heights is seen with increasing fragment size. The microsatellite analysis method and kit of the present invention are preferably designed to amplify and analyze DNA from PET tissue samples. (See Example 7 for an illustration of amplification of such samples using a method of the present invention.)
When the method or kit of the present invention is used in the analysis or detection of tumors, at least one sample of genomic DNA analyzed originates from a tumor. When a monomorphic or quasi-monomorphic locus, such as MONO-11 or MONO-15 is amplified, the size of the resulting amplified alleles can be compared to the most commonly observed allele size at that locus in the general population. The present method and kit is preferably used to diagnose or detect tumors by co-amplifying at least two different samples of DNA from the same individual, wherein one of the two samples originates from normal non-cancerous biological material.
The present invention is further explained by the following examples which should not be construed by way of limiting the scope of the present invention.
In this example, microsatellite markers in DNA isolated from tumors were compared to microsatellite markers in DNA isolated from normal tissue or cells in order to detect MSI. Specifically, microsatellite loci were amplified from paired normal/tumor DNA samples and genotyped. If one or more different alleles were present in the tumor DNA sample that were not found in normal sample from the same individual, then it was scored as MSI positive. Di-nucleotide, tetra-nucleotide and penta-nucleotide repeat microsatellite markers were analyzed for frequency of alteration to determine the relative sensitivity of particular markers to MSI. Detailed information about the specific procedures used in this example are provided herein, below.
Tissues and DNA isolation. Matched normal (blood) and neoplastic tissue samples for 39 patients were obtained from the Cooperative Human Tissue Network (hereinafter, “CHTN”) (Ohio State University, Columbus, Ohio). After surgical resection, tissue samples were frozen in liquid nitrogen and stored at −70° C. Blood samples were collected by venipuncture using vacuum tubes. DNA extraction from blood and solid tissues was performed either by standard Phenol/chloroform method (Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Press, Cold Springs Harbor, N.Y.) or with QIAamp Blood and Tissue Kit (QIAGEN, Santa Clarita, Calif.) following manufactures protocol.
PCR and Microsatellite Analysis. Fluorescently labeled primers from 275 microsatellite loci were used to amplify template DNA from normal/tumor pairs of samples. Two hundred and forty-five tetra-nucleotide repeat markers from the Research Genetics CHLC/Weber Human Screening Set Version 9.0 were evaluated (Research Genetics, Huntsville, Ala.). Additional primer sets for tetra-nucleotide and penta-nucleotide repeat markers were obtained from Promega Corporation (Madison, Wis.) (PowerPlex™ 16 System contains D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta D, vWA, D8S1179, TPOX, and FGA loci). Penta-nucleotide repeat markers TP53, Penta A, Penta B, Penta C, Penta D, Penta E, Penta F and Penta G or were custom synthesized (Promega Corporation, Madison, Wis.) using sequence data from public databases Di-nucleotide markers included for comparison purposes (D8S254, NM23, D18S35, D5S346, TP53-di, D2S123, D1S2883, D3S1611, D7S501) were obtained from PE Biosystems (now doing business as Applied Biosystems Group, Foster City, Calif.).
Markers from Research Genetics, Human Screening Set Version 9.0, were multiplexed and screened for MSI using 2.5 ng of DNA in 10 μl PCR reactions described below. Other loci were evaluated as monoplexes using 1 ng DNA in 25 μl PCR reactions as described below. All markers were PCR amplified under the same conditions in using a Perkin-Elmer® GeneAmp PCR System 9600 Thermal Cycler, except as indicated otherwise below. Microsatellite markers from the PowerPlex™ 16 System (Technical Manual #TMD012, Promega Corporation, Madison, Wis.) and dinucleotide repeat markers from the Microsatellite RER Assay system (see product literature from PE Biosystems, non Applied Biosystems, Foster City, Calif.) were analyzed following manufacture's protocol.
TABLE 1
10 μl triplex PCR reaction for Research Genetics markers
Volume
PCR Master Mix Component
Per Sample
Nuclease Free Water
3.30
μl
10× GoldSTHR Buffer (Promega)
1.00
μl
Primer 1
0.50
μl
Primer 2
0.50
μl
Primer 3
0.50
μl
Primer 4
0.50
μl
Primer 5
0.50
μl
Primer 6
0.50
μl
AmpliTaq Gold DNA Polymerase (5 Units/μl)
0.15
μl
(Perkin Elmer)
DNA (1 ng/μl)
2.50
μl
Total Reaction Volume
10.00
μl
TABLE 2
25 μl PCR reaction
Volume
PCR Master Mix Component
Per Sample
Nuclease Free Water
17.45
μl
GoldSTHR 10× Buffer (Promega)
2.50
μl
10× Primer Pair Mix (10 μM)
2.50
μl
AmpliTaq Gold DNA Polymerase (5 Units/μl)
0.05
μl
(Perkin Elmer)
Template DNA (0.4 ng/μl)
2.50
μl
Total Reaction Volume
25.00
μl
TABLE 3
Cycling profile for PE 9600 Thermal Cycler
1
cycle
95° C. for 11 minutes
1
cycle
96° C. for 1 minute
10
cycles
94° C. for 30 seconds
ramp 68 seconds to 56° C., hold for 30 seconds
ramp 50 seconds to 70° C., hold for 45 seconds
20
cycles
94° C. for 30 seconds
ramp 60 seconds to 56° C., hold for 30 seconds
ramp 50 seconds to 70° C., hold for 45 seconds
1
cycle
60° C. for 30 minutes
1
cycle
Soak 4° C.
One microliter of PCR product (Research Genetics markers were first diluted 1:4 in 1× GoldSTHR PCR buffer) was combined with 1 μl of Internal Lane Standard (Promega Corporation, Madison, Wis.) and 24 μl deionized formamide. Samples were denatured by heating at 95° C. for 3 minutes and immediately chilled on ice for 3 minutes. Separation and detection of amplified fragments was performed on an ABI PRISM® 310 Genetic Analyzer following the standard protocol recommended in the User's Manual with the following settings: 5 second Injection Time, 15 kV Injection Voltage, 15 kV Run Voltage, 60° C. Run Temperature, and 28 minute Run Time.
Assay Interpretation. Identification of normal and tumor allele sizes was accomplished by examining the appropriate electropherogram from the ABI PRISM 310 Genetic Analyzer (Applied Biosystems) and determining the predominate peaks for each locus. One or two peaks or alleles can be present for each locus in normal samples depending upon whether individual is homozygous or heterozygous for a particular marker. Allelic patterns or genotypes for normal and tumor pairs were compared and scored as MSI positive if one or more different alleles were present in the tumor DNA samples that were not found in normal sample from the same individual.
A wide range in frequency of alteration was observed in between samples and between markers evaluated. Samples were divided into two groups based on the frequency of alteration using guidelines recommended in NCI Workshop on MSI (Boland et al., 1998). Samples with greater that 30-40% of markers exhibiting alteration in tumor samples were classified as MSI-H and <30-40% as MSI-L. Samples with no alterations were classified as microsatellite stable (MSS). Based on this definition of MSI phenotypes, nine samples were classified as MSI-H and the remaining 30 as either MSI-L or MSS.
The tetra- and penta-nucleotide repeat loci exhibited the smallest amount of stutter of the loci screened, above. See
Due to the highly informative nature of mono-nucleotide repeat loci in determining MSI phenotype, we also investigated poly (A) regions of the human genome as a new source of markers for MSI assays. To accomplish this, mono-nucleotide repeats were identified from GenBank using BLASTN (Altschul, et al. 1990 J. Mol. Biol. 215:402-410) searches for (A)30(N)30 sequences. The (N)30 sequence was added to eliminate frequent mRNA hits and to assure that flanking sequence was available for designing primers for PCR. Next, flanking primers were designed for 33 GenBank DNA sequences using Oligo Primer Analysis Software version 6.0 (National Biosciences, Inc., Plymouth, Minn.) to amplify the region containing the poly (A) repeat. Evaluation of loci was performed using 9 MSI-H and 30 MSS colon cancer samples and corresponding normal DNA samples. Protocols for PCR, detection and analysis are described in Example 1.
Two characteristics were screened for in the new loci. First, loci were screened for which could detect MSI in the MSI-H group and not in the MSS group. Secondly, loci were selected on the basis of being monomorphic or nearly monomorphic (quasi-monomorphic). The monomorphic nature of the new loci was determined by genotyping 96 samples from 5 racial groups (African-American, Asian-American, Caucasian-American, Hispanic-American and Indian-American). Screening of 33 mono-nucleotide repeat loci revealed four new mono-nucleotide repeat loci (MON0-3, MONO-11, MONO-15, and MONO-19) that displayed high sensitivity to MSI (Table 4 and
TABLE 4
Results from Screening of Mono-nucleotide Repeat Loci
MSI Type
BAT-25
BAT-26
MONO-3
MONO-11
MONO-15
MONO-19
MSI-H
100%
100%
100%
100%
100%
100%
MSI-L or
0%
0%
0%
0%
0%
0%
MSS
TABLE 5
Polymorphism Level of Mono-nucleotide Repeat Loci
BAT-25
BAT-26
MONO-11
MONO-15
% Homozygosity
95%
95%
89%
99%
(82/86)
(89/94)
(76/85)
(87/88)
% Monomorphic
95%
95%
89%
99%
A population study was conducted in which 93 samples from African-American individuals were genotyped using preferred microsatellite loci selected as candidates for multiplexing in the studies illustrated in Examples 1 and 2, above. See Table 6, below, and Table 3, above, for the amplification conditions used. See Table 7, below, for a list of the loci amplified and analyzed in this study. In addition, a pooled Human Diversity DNA sample and control CEPH DNAs 1331-1 and 1331-2 (Coriell Cell Repository, Camden, N.J.) were included in the screening population. African-American samples were used because they contain the greatest genetic diversity found in all racial groups.
To facilitate screening of 96 samples with 22 different microsatellite markers, selected markers were multiplexed in small groups of three. Multiplexed primer sets were used to amplify individual sample DNAs using conditions described below.
TABLE 6
25 μl PCR reaction
Volume
PCR Master Mix Component
Per Sample
Nuclease Free Water
17.30
μl
GoldSTHR 10× Buffer (Promega)
2.50
μl
10× Triplex Primer Mix (1 to 10 μM each)
2.50
μl
AmpliTaq Gold DNA Polymerase (5 Units/μl)
0.20
μl
(Perkin Elmer)
Template DNA (0.4 ng/μl)
2.50
μl
Total Reaction Volume
25.00
μl
The results of the population study are summarized in Table 7. The size of the smallest and largest allele for each locus was identified to determine allele size range. To calculate percent stutter, the peak height of the stutter band was divided by the peak height generated by the true allele, then multiplied by 100. Minimum and maximum stutter values were calculated for each locus as well as the combined average percent stutter from 20 random samples.
TABLE 7
Summary of Results of Population Study
Allele Size Range
Average
Locus
GenBank ID #
GenBank
Pop Study
% Stutter
BAT-25
U63834
18 bp
42 bp
ND
BAT-26
U41210
18 bp
12 bp
ND
MONO-11
AC007684
ND
14 bp
ND
MONO-15
AC007684
ND
6 bp
ND
D1S547
G07828
46 bp
26 bp
4.9
D1S518
G07854
48 bp
ND
ND
D1S1677
G09926
40 bp
35 bp
9.7
D2S1790
G08190
68 bp
44 bp
7.8
D3S2432
G08240
67 bp
40 bp
8.0
D5S818
G08446
36 bp
ND
ND
D5S2849
G15752
40 bp
37 bp
5.5
D6S1053
G08556
48 bp
36 bp
6.9
D7S1808
G08643
58 bp
44 bp
7.6
D7S3046
G10353
48 bp
71 bp
12.9
D7S3070
G27340
44 bp
44 bp
10.3
D8S1179
G08710
44 bp
ND
ND
D9S2169
G08748
12 bp
ND
ND
D10S677
G12433
28 bp
40 bp
5.5
D10S1426
G08812
28 bp
ND
ND
D10S2470
G10285
48 bp
29 bp
5.9
D12S391
G08921
52 bp
48 bp
7.6
D17S1294
G07967
44 bp
28 bp
7.2
D17S1299
G07952
40 bp
ND
ND
D18S51
L18333
76 bp
ND
ND
FGA
M64982
120 bp
ND
ND
In order to develop a multiplex MSI assay system which is highly sensitive to MSI, with minimal stutter, and minimal incidence of LOH, the criteria listed in Table 8, below, were used to screen loci identified in the Examples above as possible candidates for use in MSI analysis:
TABLE 8
MSI Loci Specifications for Use in Multiplex
Monoplex
specifications
Tetra-
>70% MSI in MSI-H samples
nucleotides
<8% MSI with MSI-L and MSS samples
LOH <14% in MSI-H samples
Average % Stutter <13%
Mono-
100% MSI in MSI-H samples
nucleotides
0% MSI with MSI-L and MSS samples
Multiplex
9 loci; 3 mono- and 6 tetra-nucleotides
specifications
All amplicons <250 bp
Robust amplification of DNA from PET samples
Robust amplification of 1 to 2 ng DNA
Balanced peak heights between all loci in multiplex
Sensitivity >99.9%
Specificity >99.9%
The loci listed in Table 9, below, were identified as loci meeting the specifications listed in Table 8, above.
TABLE 9
Preferred Microsatellite Loci for Multiplexing
GenBank
% MSI
Repeat
Accession
Primer
% MSI
% LOH
(MSS or
Locus
Type
No.
SEQ. ID.
(MSI-H)
(MSI-H)
MSI-L)
BAT-25
Mono
U63834
1, 2
100%
0%
0%
BAT-26
Mono
U41210
3, 4
100%
0%
0%
MONO-11
Mono
AC007684
5, 6
100%
0%
0%
MONO-15
Mono
AC007684
7, 8
100%
0%
0%
D1S518
Tetra
G07854
9, 10
83%
0%
0%
D1S547
Tetra
G07828
11, 12
78%
3%
0%
D1S1677
Tetra
G09926
13, 14
80%
0%
3%
D2S1790
Tetra
G08190
15, 16
82%
3%
3%
D3S2432
Tetra
G08240
17, 18
83%
3%
3%
D5S818
Tetra
G08446
19, 20
72%
14%
3%
D5S2849
Tetra
G15752
21, 22
76%
7%
0%
D6S1053
Tetra
G08556
23, 24
76%
0%
0%
D7S1808
Tetra
G08643
25, 26
90%
0%
0%
D7S3046
Tetra
G10353
27, 28
93%
0%
0%
D7S3070
Tetra
G27340
29, 30
86%
3%
3%
D8S1179
Tetra
G08710
31, 32
75%
7%
7%
D9S2169
Tetra
G08748
33, 34
72%
3%
0%
D10S1426
Tetra
G08812
35, 36
86%
3%
0%
D10S2470
Tetra
G10285
37, 38
83%
3%
0%
D12S391
Tetra
G08921
39, 40
79%
3%
0%
D17S1294
Tetra
G07967
41, 42
86%
3%
0%
D17S1299
Tetra
G07952
43, 44
79%
3%
0%
D18S51
Tetra
L18333
45, 46
75%
7%
0%
FGA
Tetra
M64982
47, 48
82%
7%
7%
* MSI-H samples: N = 29 and MSI-L/S samples N = 30.
In order to determine the underlying cause of MSI in MSI-H tumor samples used in developing the Multiplex MSI Assay, protein expression levels for MLH1 and MSH2 genes were examined. Immunohistochemical analysis of paraffin-embedded tissues from eight MSI-H samples was performed as described in Thibodeau et al. (Cancer Research 58, 1713-1718). Lack of protein expression in MLH1 and MSH2 genes is expected in tumor samples exhibiting high levels of MSI and is an indication of dysfunctional mismatch repair system.
The results of the immunohistochemical assays on the MSI-H tumor samples is shown in Table 10.
TABLE 10
Protein Expression of MSH1 and
MSH2 in MSI-H Cancer Samples
MSI
Protein expression
Tumor Sample
Source
Phenotype
HMLH1
HMSH2
C172
CHTN
MSI-H
−
+
C404
CHTN
MSI-H
−
+
C507
CHTN
MSI-H
−
+
C546
CHTN
MSI-H
−
+
C624
CHTN
MSI-H
ND
ND
C710
CHTN
MSI-H
−
+
C1166
CHTN
MSI-H
−
+
C5412
CHTN
MSI-H
−
+
S15945
CHTN
MSI-H
+
+
A-1
Mayo Clinic
MSI-H
−
+
A-5
Mayo Clinic
MSI-H
−
+
A-7
Mayo Clinic
MSI-H
+
−
A-15
Mayo Clinic
MSI-H
−
+
A-19
Mayo Clinic
MSI-H
−
+
A-29
Mayo Clinic
MSI-H
−
+
A-49
Mayo Clinic
MSI-H
+
−
A-50
Mayo Clinic
MSI-H
−
+
A-73
Mayo Clinic
MSI-H
−
+
A-102
Mayo Clinic
MSI-H
+
−
B-2
Mayo Clinic
MSI-H
−
+
B-52
Mayo Clinic
MSI-H
−
+
B-61
Mayo Clinic
MSI-H
−
+
B-75
Mayo Clinic
MSI-H
−
+
B-76
Mayo Clinic
MSI-H
−
+
B-93
Mayo Clinic
MSI-H
−
+
B-107
Mayo Clinic
MSI-H
−
+
B-155
Mayo Clinic
MSI-H
−
+
B-164
Mayo Clinic
MSI-H
−
+
B-166
Mayo Clinic
MSI-H
−
+
B-173
Mayo Clinic
MSI-H
−
+
B-199
Mayo Clinic
MSI-H
−
+
B-209
Mayo Clinic
MSI-H
−
+
B-210
Mayo Clinic
MSI-H
−
+
B-268
Mayo Clinic
MSI-H
−
+
B-299
Mayo Clinic
MSI-H
−
+
B-334
Mayo Clinic
MSI-H
−
+
B-379
Mayo Clinic
MSI-H
−
+
B-402
Mayo Clinic
MSI-H
−
+
B-564
Mayo Clinic
MSI-H
−
+
Once the best loci were selected for use in designing multiplexes to be analyzed according to the methods of the present invention, problems associated with multiplex PCR and incompatibility between loci needed to be overcome. This required careful primer design and extensive trial and error to find loci that were capable of simultaneous amplification using a single set of PCR conditions. Problems encountered included: (1) primer-primer interactions that occurred when large number of oligos were combined in a single PCR reaction, (2) primer design limitations due to sequence constraints at a particular locus (e.g., minimum size of amplicon allowed by DNA sequence, sub-optimal % GC of primers, difficulty balancing Tm's for all primers under uniform PCR conditions, difficulty in finding primers with desirable thermal profiles to minimize non-specific amplification, hairpin formation and self dimerization of primers, homology to other repeat sequences in human genome), and (3) multiplex design allowing separation of all 9 loci within limited size range of 250 bp.
Based on extensive evaluation of close to 300 microsatellite markers described in Examples 1 through 5, nine loci were selected for the preferred MSI Multiplex Assay (Table 11). Three loci are monoplex repeats (BAT-25, BAT-26 and MONO-15) and six were tetra-nucleotide repeats (D7S3046, D10 S1426, D10 S2470, D7S3070, D17S1294, D7S1808). These loci represent the best known set of loci known for determining MSI in tumor samples. Results of MSI analysis on 29 MSI-H and 30 MSI-L or MSS colon cancer samples using the preferred nine-locus multiplex are summarized in
A typical example of MSI Multiplex is shown in
TABLE 11
MSI Multiplex Assay Loci and Primers
GenBank
Repeat
Size
Primer 1
Primer 2
Locus
ID No.
Type
Dye
Range
(SEQ. ID.)
(SEQ. ID.)
BAT-25
U63834
Mono
TMR
118-127
1
60
D10S1426
G08812
Tetra
TMR
152-173
57
58
D3S2432
G08240
Tetra
TMR
198-234
17
59
BAT-26
U41210
Mono
FL
103-116
61
62
D7S3046
G10353
Tetra
FL
122-163
55
56
D7S3070
G27340
Tetra
FL
186-249
53
54
MONO-15
AC007684
Mono
JOE
115-117
7
8
D1S518
G07854
Tetra
JOE
136-178
49
50
D7S1808
G08643
Tetra
JOE
190-218
51
52
Protocol for MSI Multiplex Assay. Template DNA from normal and tumor tissues obtained from same individual were purified using QIAamp Blood and Tissue Kit (QIAGEN, Santa Clarita, Calif.) following manufactures protocol. Two nanograms of template DNA in a 25 μl reaction volume was PCR amplified using protocol detailed in Table 12, below, using the cycling profile described in Table 3, above.
TABLE 12
Amplification Mix for MSI Multiplex Assay
PCR Master Mix Component
Volume Per Sample
Nuclease Free Water
17.00
μl
GoldSTHR 10× Buffer (Promega)
2.50
μl
Primer Pair Mix (10 μM)
2.50
μl
AmpliTaq Gold DNA Polymerase (Perkin Elmer)
0.50
μl
Template DNA (0.8 ng/μl)
2.50
μl
Total Reaction Volume
25.00
μl
One microliter of PCR product was combined with 1 μl of Internal Lane Standard (Promega Corporation, Madison, Wis.) and 24 μl deionized formamide. Samples were denatured by heating at 95° C. for 3 minutes and immediately chilled on ice for 3 minutes. Separation and detection of amplified fragments was performed on an ABI PRISM 310 Genetic Analyzer following the standard protocol recommended in the User's Manual with the following settings:
Run Module:
GS STR POP4 (Filter set A)
Injection Time:
4 seconds
Injection Voltage:
15 kV
Run Voltage:
15 kV
Run Temperature:
60° C.
Run Time:
24 minutes
Identification of normal and tumor allele amplicon sizes was accomplished by examining the appropriated electropherogram from the ABI PRISM 310 Genetic Analyzer and determining the predominate peaks for each locus. One or two peaks or alleles were present for each locus in normal samples depending upon whether individual was homozygous or heterozygous for a particular marker. Allelic patterns or genotypes for normal and tumor pairs were compared and scored as MSI positive if one or more different alleles were present in the tumor DNA samples that were not found in normal sample from the same individual. Typical examples of results obtained using multiplex designed for MSI analysis are shown in
Microsatellite loci selected for the preferred multiplex were evaluated for their ability to amplify DNA from formalin-fixed paraffin-embedded samples. DNA was extracted from three 10 micron sections cut from PET blocks using QIAamp Tissue Kit (Qiagen, Santa Clarita, Calif.) according to the manufacture's instructions with the following modifications. One hundred microliters of QIAGEN AE buffer preheated to 70° C. was added to column, incubated for 5 minutes, centrifuged, then reapplied to column for second elution. Two microliters (out of 100 μl) of purified DNA solution was used as template for PCR reactions. The nine locus multiplexed primer set described in Example 6 was used to amplify DNA from PET samples. The results indicate that the MSI Multiplex is capable of amplifying DNA from difficult and commonly used PET samples (
While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.
Nassif, Nadine, Bacher, Jeffery W., Flanagan, Laura
| Patent | Priority | Assignee | Title |
| 11104938, | Jun 20 2017 | Bio-Rad Laboratories, Inc.; BIO-RAD LABORATORIES, INC | Digital amplification assays for genetic instability |
| Patent | Priority | Assignee | Title |
| 4683195, | Oct 25 1985 | Roche Molecular Systems, Inc | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| 4683202, | Mar 28 1985 | Roche Molecular Systems, Inc | Process for amplifying nucleic acid sequences |
| 5492808, | May 05 1993 | Johns Hopkins University | Means for detecting familial colon cancer (FCC) |
| 5569753, | Dec 20 1994 | Cold Spring Harbor Laboratory | Cancer detection probes |
| 5578450, | Feb 24 1993 | Mayo Foundation for Medical Education and Research | Tumor-specific genomic instability as a prognostic indicator |
| 5591826, | Dec 02 1994 | Johns Hopkins University, The | Human MSH2 protein |
| 5645995, | Apr 12 1996 | Baylor College of Medicine | Methods for diagnosing an increased risk for breast or ovarian cancer |
| 5693470, | Dec 02 1993 | Johns Hopkins University, The | Diagnostic method employing MSH2 nucleic acids |
| 5736365, | May 05 1993 | Becton, Dickinson and Company | Multiplex nucleic acid amplification |
| 5776682, | Jun 07 1995 | Promega Corporation | Male infertility y-deletion detection battery |
| 5783390, | Jun 07 1995 | Promega Corporation | Male infertility Y-deletion detection battery |
| 5837443, | Dec 02 1993 | Johns Hopkins University, The | Diagnostic method employing MSH2 protein |
| 5840549, | Sep 18 1995 | Promega Corporation | Male infertility Y-deletion detection battery |
| 5843660, | Sep 30 1994 | Promega Corporation | Multiplex amplification of short tandem repeat loci |
| 5843757, | Aug 24 1995 | Johns Hopkins University, The | Human JTV1 gene overlaps PMS2 gene |
| 5856094, | May 12 1995 | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE THE | Method of detection of neoplastic cells |
| 5866323, | Apr 07 1995 | Medical College of Ohio | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| 5871925, | May 30 1995 | The Johns Hopkins University | Tumor classification as indication of hereditary non-polyposis colorectal carcinoma |
| 5874217, | Mar 27 1996 | SCIDERA GENOMICS, LLC; IGENITY INC | Microsatellite sequences for canine genotyping |
| 5912147, | Oct 22 1996 | HEALTH RESEARCH, INC | Rapid means of quantitating genomic instability |
| 5922855, | Dec 17 1993 | Dana-Farber Cancer Institute | Mammalian DNA mismatch repair genes MLH1 and PMS1 |
| 5935787, | Aug 31 1994 | The Johns Hopkins University | Detection of hypermutable nucleic acid sequence in tissue |
| 5952170, | Dec 16 1993 | GUARDANT HEALTH, INC | Method for diagnosing cancers |
| 6090558, | Sep 19 1997 | BIOSCIENCES ACQUISITION COMPANY; AGENA BIOSCIENCE, INC | DNA typing by mass spectrometry with polymorphic DNA repeat markers |
| 6150100, | Mar 25 1997 | Roche Diagnostics GmbH | Method for the detection of microsatellite instability for tumor diagnostics |
| 6280947, | Aug 11 1999 | Esoterix Genetic Laboratories, LLC | Methods for detecting nucleotide insertion or deletion using primer extension |
| 6331393, | May 14 1999 | SOUTHERN CALIFORNIA, UNIVERSITY OF | Process for high-throughput DNA methylation analysis |
| 6531282, | May 30 2000 | Oligotrail, LLC | Multiplex amplification and analysis of selected STR loci |
| 6844152, | Sep 15 2000 | Promega Corporation | Detection of microsatellite instability and its use in diagnosis of tumors |
| 7202031, | Sep 15 2000 | Promega Corporation | Detection of microsatellite instability and its use in diagnosis of tumors |
| 7364853, | Sep 15 2000 | Promega Corporation | Detection of microsatellite instability and its use in diagnosis of tumors |
| 20020058265, | |||
| 20070117136, | |||
| EP869188, | |||
| WO9759, | |||
| WO222879, | |||
| WO9411531, | |||
| WO9515400, | |||
| WO9606951, | |||
| WO9808980, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Apr 16 2001 | BACHER, JEFFERY W | Promega Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 033210 | /0367 | |
| Apr 16 2001 | FLANAGAN, LAURA | Promega Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 033210 | /0367 | |
| Apr 16 2001 | NASSIF, NADINE | Promega Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 033210 | /0367 | |
| Apr 25 2008 | Promega Corporation | (assignment on the face of the patent) | / | |||
| Mar 28 2019 | Promega Corporation | JPMORGAN CHASE BANK, N A , AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048790 | /0259 | |
| Mar 28 2019 | PROMEGA BIOSCIENCES, LLC | JPMORGAN CHASE BANK, N A , AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048790 | /0259 | |
| Mar 28 2019 | TERSO SOLUTIONS, INC | JPMORGAN CHASE BANK, N A , AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048790 | /0259 | |
| Mar 28 2019 | ORION SEVEN, LLC | JPMORGAN CHASE BANK, N A , AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048790 | /0259 | |
| Mar 28 2019 | PROMEGA AVIATION LLC | JPMORGAN CHASE BANK, N A , AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 048790 | /0259 |
| Date | Maintenance Fee Events |
| Sep 08 2014 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Sep 10 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Oct 24 2022 | REM: Maintenance Fee Reminder Mailed. |
| Apr 10 2023 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Mar 08 2014 | 4 years fee payment window open |
| Sep 08 2014 | 6 months grace period start (w surcharge) |
| Mar 08 2015 | patent expiry (for year 4) |
| Mar 08 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Mar 08 2018 | 8 years fee payment window open |
| Sep 08 2018 | 6 months grace period start (w surcharge) |
| Mar 08 2019 | patent expiry (for year 8) |
| Mar 08 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Mar 08 2022 | 12 years fee payment window open |
| Sep 08 2022 | 6 months grace period start (w surcharge) |
| Mar 08 2023 | patent expiry (for year 12) |
| Mar 08 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |